Research programme: diabetic nephropathies therapy - NephroGenex

Drug Profile

Research programme: diabetic nephropathies therapy - NephroGenex

Alternative Names: BST 4946; BST 4996; BST 4997; BST-605

Latest Information Update: 12 May 2006

Price : $50

At a glance

  • Originator BioStratum
  • Developer NephroGenex
  • Class Imidazoles; Piperazines; Pyridines
  • Mechanism of Action Advanced glycosylation end product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 12 May 2006 NephroGenex licenses second generation AGE compounds, including BST 605, from BioStratum
  • 17 Jun 2004 Data presented at the 64th Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
  • 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top